Overview

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)

Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and toxicity of plerixafor (AMD 3100) together with granulocyte-colony stimulating factor (G-CSF) for stem cell mobilisation, in patients with myeloma or lymphoma requiring high dose chemotherapy with stem cell rescue.
Phase:
N/A
Details
Lead Sponsor:
University of Liverpool
Collaborator:
Genzyme, a Sanofi Company
Treatments:
JM 3100
Plerixafor